Biofrontera Inc. Files S-1 Registration Statement

TL;DR

<b>Biofrontera Inc. has filed an S-1 registration statement with the SEC, indicating potential future securities offerings.</b>

AI Summary

Biofrontera Inc. (BFRIW) filed a IPO Registration (S-1) with the SEC on January 17, 2024. Biofrontera Inc. filed an S-1 registration statement with the SEC on January 17, 2024. The filing pertains to the company's securities. The company's principal executive offices are located in Woburn, MA. Biofrontera Inc. is incorporated in Delaware. The company operates in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking Biofrontera Inc., this filing contains several important signals. This S-1 filing signals Biofrontera's intention to potentially raise capital or offer new securities to the public, which could impact its financial structure and shareholder base. As a pharmaceutical preparations company, this filing is a standard step for companies looking to access capital markets for growth, research, or operational expansion.

Risk Assessment

Risk Level: low — Biofrontera Inc. shows low risk based on this filing. The filing is a standard S-1 registration statement, which is a preliminary step for potential securities offerings and does not inherently indicate immediate financial distress or significant operational changes.

Analyst Insight

Monitor Biofrontera Inc. for subsequent filings related to this S-1, such as a prospectus or pricing details, to understand the specifics of any potential securities offering.

Key Numbers

• 2024-01-17 — Filing Date (Date the S-1 registration statement was filed)
• 2024-01-16 — As of Date (Date as of which information in the filing is current)
• 0001493152-24-002533 — Accession Number (Unique identifier for the filing)
• 333-276535 — SEC File Number (SEC's file number for the registration)

Key Players & Entities

• Biofrontera Inc. (company) — Filer name
• 120 Presidential Way, Suite 330, Woburn, MA 01801 (location) — Business and mailing address
• 781-245-1325 (phone_number) — Business phone number
• DE (state) — State of incorporation
• 1231 (fiscal_year_end) — Fiscal year end
• 2834 (sic_code) — Standard Industrial Classification
• SEC (regulator) — Regulatory body
• S-1 (form_type) — Filing form type

Forward-Looking Statements

• Biofrontera Inc. will announce a specific securities offering within the next 6-12 months. (Biofrontera Inc.) — medium confidence, target: 2025-01-17

FAQ

Industry Context

Biofrontera Inc. operates within the pharmaceutical preparations sector, focusing on the development and commercialization of medical products.

Regulatory Implications

The S-1 filing is a regulatory requirement under the Securities Act of 1933 for companies intending to offer securities to the public.

What Investors Should Do

1. Review the full S-1 filing for detailed information on the proposed securities offering, if any.
2. Track Biofrontera Inc.'s stock performance and any news related to the S-1 filing.
3. Analyze the company's financial health and business strategy in light of this potential capital raise.

Key Dates

• 2024-01-17: S-1 Filing — Indicates potential future securities offerings or capital raises by Biofrontera Inc.

Year-Over-Year Comparison

This is a new S-1 filing, so there is no prior filing of the same type to compare against for direct 'vs last filing' analysis.

Key Financial Figures

• $0.001 — o shares of our common stock, par value $0.001 (the "Common Stock") and up to warrant
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
• $0.0001 — rice of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will
• $2.21 — price per share of our common stock was $2.21. The actual combined public offering pr
• $4 billion — market size is estimated to be roughly $4 billion for the three therapy types. Our primar
• $500 million — et, our targeted market is about 11% or $500 million of the total AK market (consisting of t
• $100 million — consisting of the current PDT market at $100 million and the portion of the market attribute
• $400 m — y treatments of more than 14 lesions at $400 million, assuming a tube price of $346).
• $346 — $400 million, assuming a tube price of $346). 6 Our second prescription drug lice

Filing Documents

• forms-1.htm (S-1) — 3454KB
• ex23-1.htm (EX-23.1) — 3KB
• ex107.htm (EX-FILING FEES) — 27KB
• logo_001.jpg (GRAPHIC) — 12KB
• logo_002.jpg (GRAPHIC) — 9KB
• 0001493152-24-002533.txt (&nbsp;) — 12780KB
• bfri-20230930.xsd (EX-101.SCH) — 88KB
• bfri-20230930_cal.xml (EX-101.CAL) — 104KB
• bfri-20230930_def.xml (EX-101.DEF) — 399KB
• bfri-20230930_lab.xml (EX-101.LAB) — 607KB
• bfri-20230930_pre.xml (EX-101.PRE) — 539KB
• forms-1_htm.xml (XML) — 1946KB

RISK FACTORS

RISK FACTORS 14 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 50

USE OF PROCEEDS

USE OF PROCEEDS 51 CAPITALIZATION 52 DIVIDEND POLICY 53

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 56

BUSINESS

BUSINESS 71 MANAGEMENT 81

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 86 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 90

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 93

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION 94 SHARES ELIGIBLE FOR FUTURE SALE 101 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 102 PLAN OF DISTRIBUTION 106 LEGAL MATTERS 112 EXPERTS 112 WHERE YOU CAN FIND MORE INFORMATION 112 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any related free-writing prospectus. We and the Placement Agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares and warrants offered by this prospectus, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not done anything that would permit this offering or the possession or distribution of this prospectus or any free-writing prospectus that we may provide to you in connection with the offering in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares and warrants and the distribution of this prospectus outside the United States. See "Plan of Distribution." BASIS OF PRESENTATION As used in this prospectus, unless the context otherwise requires, references to "we," "us," "our," the "Company," "Biofrontera" and similar references refer to Biofrontera Inc. References in this prospectus to the " Biofrontera Group " refer to Biofrontera AG and its consolidated subsidiaries, Biofrontera Pha

View Full Filing

View this S-1 filing on SEC EDGAR